Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits.

Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, Bennett RP, Raina J, Smith HC.

J Biol Chem. 2006 Dec 15;281(50):38122-6. Epub 2006 Oct 31.


Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC.

Nature. 2005 May 5;435(7038):108-14. Epub 2005 Apr 13. Retraction in: Nature. 2010 Jul 8;466(7303):276.


High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.

Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, Esnault C, Heidmann T, Greene WC.

Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15588-93. Epub 2006 Oct 9.


Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.

Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC.

J Biol Chem. 2007 Feb 9;282(6):3539-46. Epub 2006 Nov 16.


HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.

Kremer M, Schnierle BS.

Curr HIV Res. 2005 Oct;3(4):339-44. Review.


Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.

Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H.

J Virol. 2006 Aug;80(15):7645-57.


APOBEC3G: an intracellular centurion.

Chiu YL, Greene WC.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):689-703. doi: 10.1098/rstb.2008.0193. Review.


APOBEC3G & HTLV-1: inhibition without deamination.

Strebel K.

Retrovirology. 2005 May 29;2:37.


The cellular source for APOBEC3G's incorporation into HIV-1.

Ma J, Li X, Xu J, Zhang Q, Liu Z, Jia P, Zhou J, Guo F, You X, Yu L, Zhao L, Jiang J, Cen S.

Retrovirology. 2011 Jan 6;8:2. doi: 10.1186/1742-4690-8-2. Retraction in: Retrovirology. 2011;8:88.


The roles of APOBEC3G complexes in the incorporation of APOBEC3G into HIV-1.

Ma J, Li X, Xu J, Zhang Q, Liu Z, Jia P, Zhou J, Guo F, You X, Yu L, Zhao L, Jiang J, Cen S.

PLoS One. 2013 Oct 2;8(10):e74892. doi: 10.1371/journal.pone.0074892. eCollection 2013.


Analysis of Vif-induced APOBEC3G degradation using an alpha-complementation assay.

Fang L, Landau NR.

Virology. 2007 Mar 1;359(1):162-9. Epub 2006 Oct 17.


Biochemical fractionation and purification of high-molecular-mass APOBEC3G complexes.

Chiu YL.

Methods Mol Biol. 2011;718:185-206. doi: 10.1007/978-1-61779-018-8_12.


Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.

Shirakawa K, Takaori-Kondo A, Kobayashi M, Tomonaga M, Izumi T, Fukunaga K, Sasada A, Abudu A, Miyauchi Y, Akari H, Iwai K, Uchiyama T.

Virology. 2006 Jan 20;344(2):263-6. Epub 2005 Nov 21.


APOBEC3G targets human T-cell leukemia virus type 1.

Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T.

Retrovirology. 2005 May 19;2:32.


APOBEC3G levels predict rates of progression to AIDS.

Jin X, Wu H, Smith H.

Retrovirology. 2007 Mar 20;4:20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk